First Time Generics Approved In 1999
1See related information
You may also be interested in...
CDER received 140 NDAs during 1999. CBER reports 39 new product license applications were submitted in 1999, ten more than in 1998. CBER's approvals for 1999 included four new therapeutic BLA approvals, one NDA for a biologic and one BLA for a significant new indication. (1"The Pink Sheet" Jan. 17, p. 16) omitted BioTime's Hextend for hypovolemia during surgery and counted a different number of new therapeutic BLA approvals. The average time for approval of the five new biologics was 17.1 months. The number of first time generics approved in 1999 was 43 (2"The Pink Sheet" Jan 17, p. 14)
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.